TLDR Checkpoint inhibitor therapy can cause skin issues, from mild rashes to severe reactions.
The document discussed the increasing use of biologic therapies targeting immune checkpoints, such as CTLA-4 and PD-1/PD-L1, which led to a range of immune-related adverse events (irAEs), particularly affecting the skin. The severity of these cutaneous irAEs ranged from mild dermatitis to severe toxic epidermal necrolysis, with the most common being nonspecific maculopapular rash and pruritus. The document also reported a case of a patient with metastatic renal cell carcinoma (mRCC) undergoing immune checkpoint inhibitors therapy who developed a psoriasiform skin lesion.
87 citations
,
December 2016 in “British journal of dermatology/British journal of dermatology, Supplement” Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.
14 citations
,
February 2023 in “Frontiers in immunology” Immune checkpoint inhibitors can cause skin issues but are linked to better cancer outcomes.
26 citations
,
October 2018 in “Clinical & Translational Oncology” Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.
179 citations
,
October 2018 in “American Journal of Clinical Dermatology” Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.
37 citations
,
November 2017 in “Medical Sciences” Melanoma's complexity requires personalized treatments due to key genetic mutations and tumor-initiating cells.
